Literature DB >> 15750761

Immune reconstitution inflammatory syndrome (IRIS)--another new disease entity following treatment initiation of HIV infection.

F D Goebel1.   

Abstract

After the introduction of highly active antiretroviral therapy (HAART) in 1995 it took 3 years to recognize the new syndrome of lipodystrophy as a long-term complication of HAART [1]. It was found to be a direct toxic consequence of the various drugs used in combination regimens. Another 2 years later, an additional syndrome was described in patients who recently initiated HAART-the immune reconstitution inflammatory syndrome (IRIS) [2-4]. Although already recognized in the pre-HIV era in patients with treatment for tuberculosis [5, 6] and leprosy [7], it became substantially more frequent in HIV-infected patients on HAART. The term IRIS describes a collection of different inflammatory disorders which are associated with paradoxical deterioration of various preexisting infectious processes following commencement of HAART in HIV-infected patients. These preexisting infections in individuals with IRIS may have been previously diagnosed and treated or may have been symptomless and later revealed by the patient's improved capacity to mount an inflammatory response.

Entities:  

Mesh:

Year:  2005        PMID: 15750761     DOI: 10.1007/s15010-005-6105-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  9 in total

1.  Severe non-specific immune reconstitution inflammatory syndrome (IRIS) presenting with graft-versus-host disease-like colitis.

Authors:  S Reu; J Neumann; R Draenert
Journal:  Infection       Date:  2014-01-28       Impact factor: 3.553

2.  Two patients coinfected with Mycobacterium leprae and human immunodeficiency virus type 1 and naive for antiretroviral therapy who exhibited type 1 leprosy reactions mimicking the immune reconstitution inflammatory syndrome.

Authors:  M A B Trindade; N Y S Valente; M I P Manini; M D F Takahashi; C F D Anjos; G Benard; B Naafs
Journal:  J Clin Microbiol       Date:  2006-10-04       Impact factor: 5.948

3.  The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children.

Authors:  Judy Orikiiriza; Sabrina Bakeera-Kitaka; Victor Musiime; Edison A Mworozi; Peter Mugyenyi; David R Boulware
Journal:  AIDS       Date:  2010-08-24       Impact factor: 4.177

4.  Immune cellular parameters of leprosy and human immunodeficiency virus-1 co-infected subjects.

Authors:  Karina I Carvalho; Solange Maeda; Luciana Marti; Jane Yamashita; Patrick A J Haslett; Esper G Kallas
Journal:  Immunology       Date:  2008-02-12       Impact factor: 7.397

5.  Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal.

Authors:  Amanda Mocroft; Jonathan A C Sterne; Matthias Egger; Margaret May; Sophie Grabar; Hansjakob Furrer; Caroline Sabin; Gerd Fatkenheuer; Amy Justice; Peter Reiss; Antonella d'Arminio Monforte; John Gill; Robert Hogg; Fabrice Bonnet; Mari Kitahata; Schlomo Staszewski; Jordi Casabona; Ross Harris; Michael Saag
Journal:  Clin Infect Dis       Date:  2009-04-15       Impact factor: 9.079

6.  Hansen's disease with HIV: a case of immune reconstitution disease.

Authors:  Dominic Chow; Leila Okinaka; Scott Souza; Cecilia Shikuma; Alan Tice
Journal:  Hawaii Med J       Date:  2009-03

7.  Molluscum contagiosum as a skin manifestation of immune reconstitution inflammatory syndrome in an AIDS patient who is receiving HAART.

Authors:  Kyung Uk Sung; Hyo Eun Lee; Won Rak Choi; Min Cheol Seo; Hee Jung Yoon
Journal:  Korean J Fam Med       Date:  2012-05-24

8.  Immune reconstitution inflammatory syndrome unmasking erythema nodosum leprosum: a rare case report.

Authors:  Geeta Kiran Arakkal; Sudha Vani Damarla; Geetha Madhuri Chanda
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

9.  Modelling the impact of antiretroviral use in resource-poor settings.

Authors:  Rebecca F Baggaley; Geoff P Garnett; Neil M Ferguson
Journal:  PLoS Med       Date:  2006-03-14       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.